Cargando…
BDNF exon IV promoter methylation and antidepressant action: a complex interplay
BACKGROUND: BDNF exon IV promoter methylation is a potential biomarker for treatment response to antidepressants in MDD. We have previously shown CpG-87 methylation as a successful biomarker for the prediction of non-response to monoaminergic antidepressants like the SSRI Fluoxetine or the SNRI Venl...
Autores principales: | Pathak, Hansi, Borchert, Anton, Garaali, Sara, Burkert, Alexandra, Frieling, Helge |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9793565/ https://www.ncbi.nlm.nih.gov/pubmed/36572893 http://dx.doi.org/10.1186/s13148-022-01415-3 |
Ejemplares similares
-
BDNF Plasma Levels and BDNF Exon IV Promoter Methylation as Predictors for Antidepressant Treatment Response
por: Lieb, Klaus, et al.
Publicado: (2018) -
Limitations of lymphoblastoid cell lines for functional analysis of SNPs
por: Pathak, Hansi, et al.
Publicado: (2017) -
Dysregulated Methylation Patterns in Exon IV of the Brain-Derived Neurotrophic Factor (BDNF) Gene in Nicotine Dependence and Changes in BDNF Plasma Levels During Smoking Cessation
por: Abdelkhalek, Kerim, et al.
Publicado: (2022) -
Comparison of methylation estimates obtained via MinION nanopore sequencing and sanger bisulfite sequencing in the TRPA1 promoter region
por: Gombert, Sara, et al.
Publicado: (2023) -
Effects of BDNF Polymorphisms on Antidepressant Action
por: Tsai, Shih-Jen, et al.
Publicado: (2010)